Premium
Can we use statins to prevent stroke in Fabry disease?
Author(s) -
Politei J. M.
Publication year - 2009
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1007/s10545-009-1156-2
Subject(s) - globotriaosylceramide , fabry disease , medicine , stroke (engine) , disease , lysosomal storage disease , vascular disease , fabry's disease , clinical trial , neuroprotection , white matter , cardiology , magnetic resonance imaging , mechanical engineering , engineering , radiology
Summary Fabry disease is a rare, X‐linked lysosomal storage disease caused by an inborn deficiency of α‐galactosidase A, which results in the progressive accumulation of globotriaosylceramide and other neutral glycolipids in a range of cells and tissues. In association with the renal and cardiac insufficiency, cerebrovascular complications can result in the death of the patients. Several mechanisms causing vascular damage that leads to the development of deep‐white matter lesions have been described. Recent clinical trials strongly suggest that statins protect against stroke by neuroprotective properties or pleiotropic effects. Aim: To evaluate evidence and potential beneficial effects of statins in the vasculopathy of Fabry disease.